Nuvation Bio Inc. Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit)
Nuvation Bio Inc. (NUVB) reported Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) of $471.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit · last filed 2026-08-06
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for the quarter ending 2026-06-30 was $471.00K, a 27.09% decline year-over-year.
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for the quarter ending 2026-03-31 was $268.00K.
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for the quarter ending 2025-12-31 was $1.01M.
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for the quarter ending 2025-09-30 was $313.00K, a 57.82% decline year-over-year.
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for fiscal 2025 was $1.50M.
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for fiscal 2024 was -$537.00K.
- Nuvation Bio Inc. translation adjustment functional to reporting currency, tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 3 month | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 3 month as first filed | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 6 month | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 6 month as first filed | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 9 month | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 9 month as first filed | Translation Adjustment Functional to Reporting Currency, Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $471.00K 10-Q · filed 2026-08-06 | $739.00K 10-Q · filed 2026-08-06 | $1.75M derived: sum of 3 quarters · filed 2026-08-06 | $2.06M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $268.00K 10-Q · filed 2026-05-04 | $1.27M derived: sum of 2 quarters · filed 2026-05-04 | $1.59M derived: sum of 3 quarters · filed 2026-05-04 | $2.23M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.32M derived: sum of 2 quarters · filed 2026-03-02 | $1.97M derived: sum of 3 quarters · filed 2026-08-06 | $1.50M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $313.00K 10-Q · filed 2025-11-03 | $959.00K derived: sum of 2 quarters · filed 2026-08-06 | $495.00K 10-Q · filed 2025-11-03 | -$637.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $646.00K 10-Q · filed 2026-08-06 | $182.00K 10-Q · filed 2026-08-06 | -$950.00K derived: sum of 3 quarters · filed 2026-08-06 | -$208.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$465.00K 10-Q · filed 2026-05-04 | -$1.60M derived: sum of 2 quarters · filed 2026-05-04 | -$854.00K derived: sum of 3 quarters · filed 2026-05-04 | -$1.00M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | -$1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$389.00K derived: sum of 2 quarters · filed 2026-03-02 | -$537.00K derived: sum of 3 quarters · filed 2026-03-02 | -$537.00K 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $742.00K 10-Q · filed 2025-11-03 | -$742.00K 10-Q · filed 2024-11-06 | $594.00K derived: sum of 2 quarters · filed 2025-11-03 | $594.00K 10-Q · filed 2025-11-03 | -$594.00K 10-Q · filed 2024-11-06 | $594.00K derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | -$148.00K 10-Q · filed 2025-08-07 | $148.00K 10-Q · filed 2024-08-05 | -$148.00K 10-Q · filed 2025-08-07 | $148.00K 10-Q · filed 2024-08-05 | -$148.00K derived: sum of 3 quarters · filed 2025-08-07 | -$148.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-05-07 | $0.00 derived: sum of 3 quarters · filed 2025-05-07 | $0.00 derived: sum of 4 quarters · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |